New data at ASCO Show Gleevec ® Novartis drug Tasigna ® than for patients with newly diagnosed CML
June 7th, 2010 | 
Author: New Data at ASCO Show Novartis Drug Tasigna® Surpasses Gleevec® for Newly Diagnosed CML Patients
Novartis announced today 18-month results showing that Tasigna® capsules significantly surpass the efficacy of Gleevec® tablets* in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
Read more on PR Newswire via Yahoo! Finance
Related Blogs
- Hanes® and JetBlue Airways Take Comfort to New Heights – Yahoo …
- The Lowdown on Leukemia | Mesothelioma Incidence
- New therapy mounts double-barreled attack on leukemia, report UF …
- Combination Therapy Can Treat Chronic Myelogenous Leukemia (CML …
- Yahoo! Finance – Programming Blog
Posted in 
Tags: 
